The payment will include equipment and inventory payments and gives ZLB Behring full worldwide rights to CytoGam.
CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV) disease associated with transplantation of the kidney, lung, liver, pancreas and heart.
MedImmune said it may receive another $70 million from ZLB Behring when certain, undisclosed sales milestones are achieved. MedImmune said it sold the drug because it no longer fits into the focus of its development pipeline. The company is focused on the areas of infectious diseases, cancer and inflammatory diseases.